Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Selling the End of AIDS

As slogans anticipating an end to the AIDS epidemic gain popularity, skeptics worry that such promises are hollow and unrealistically ambitious, and that failure to deliver will ultimately set back efforts to combat HIV.

Published
01 October 2014
From
Poz
Late diagnosis of HIV blamed on Coalition's health reforms

Health experts are reporting disturbing increases in the number of people being diagnosed late with the HIV virus in England. They warn that healthcare reforms, which, they say, have "fragmented" a previously "seamless sexual health service", may be a major reason for the delays, and have called for an investigation.

Published
29 September 2014
From
The Independent
Only half of gay and bisexual men diagnosed with HIV received care and treatment in 2010

Among gay and bisexual men in the United States who have been diagnosed with HIV, only half are receiving care and treatment for their infection, according to a new analysis by the Centers for Disease Control and Prevention. And just 42 percent have achieved viral suppression – meaning their virus is under control at a level that helps keep them healthy and also greatly reduces their risk of transmitting HIV to others.

Published
29 September 2014
From
CDC press release
Patent landscape for hepatitis issued by WHO

The World Health Organization has published an analysis of the patent situation for new hepatitis treatments, and a call for possible pharmaceutical products for prequalification.

Published
29 September 2014
From
Intellectual Property Watch
Nearly half of HIV-positive gay men could benefit from being vaccinated against HPV, say Irish researchers

A study of gay men in Ireland that has investigated the prevalence of infection with human papillomavirus (HPV), some types of which cause genital warts and cervical,

Published
29 September 2014
By
Gus Cairns
Doctor treats Ebola with HIV drug in Liberia - seemingly successfully

A doctor in rural Liberia inundated with Ebola patients says he's had good results with a treatment he tried out of sheer desperation: an HIV drug. Dr. Gobee Logan has given the drug, lamivudine, to 15 Ebola patients, and all but two survived. That's a 7% mortality rate whereas across West Africa, the virus has killed 70% of its victims.

Published
27 September 2014
From
CNN
Countries ready to “Fast Track” response to end the AIDS epidemic by 2030

High-level panel emphasizes fragile five-year window for rapid and massive acceleration of HIV treatment and prevention services. New agreement to reduce cost of viral load tests for HIV to below US$ 10 will improve the quality of life for millions of people on HIV treatment

Published
26 September 2014
From
UNAIDS
Roche launches Global Access Program for HIV viral load testing

To support the Global Access Program, Roche has committed to expanding access to its COBAS® AmpliPrep/COBAS TaqMan HIV-1 Test version 2.0 through a special pricing scheme for qualifying organizations in eligible countries.

Published
26 September 2014
From
Roche press release
Hard choices in Russia as the final HIV grant proposal is submitted

The concept note delivered on 8 September for Russia's last HIV grant from the Global Fund was a perfect illustration of the conundrum facing a growing number of Eastern European/Central Asian countries: how to do more with less to fight a widening HIV epidemic. As more countries from the region 'graduate' from Global Fund eligibility due to their income classification, the funds that they could once count on to support prevention, harm reduction and other programs targeting vulnerable populations are disappearing. And there is little evidence that most national budgets are prepared or able to fill the vacuum.

Published
25 September 2014
From
Aidspan
Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

The studies demonstrated that the single tablet regimen comprising elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF), was non-inferior to Gilead’s Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL at 48 weeks of therapy. In addition, E/C/F/TAF demonstrated more favorable renal and bone safety compared to Stribild.

Published
25 September 2014
From
Gilead press release

Filter by country